Drug intelligence / Profile preview

KNT-0916

Development stage: Phase 1
Lead developer: KinoTeck Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KNT-0916 is an oral, small molecule inhibitor targeting the type 2 fibroblast growth factor receptor (FGFR2). It is being developed for the treatment of unresectable or metastatic solid tumors harboring FGFR2 alterations. The drug acts as an FGFR2 antagonist, aiming to block aberrant signaling pathways associated with tumor growth and progression in cancers with FGFR2 abnormalities. Clinical development is currently at Phase 1, focusing on evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients who have failed prior systemic therapy[1][2][3][4].

Targets

FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on KNT-0916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNT-0916.

Explore the full profile